For those who cannot easily make trips far outside their immediate area, the closure of a pharmacy can increase the ...

His parents have now filed a lawsuit against both the pharmacy benefits-management company and Walgreens, claiming they are responsible for their son's death. The Schmidtknechts' ...

Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

Walgreens Boots Alliance is being taken private by Sycamore Partners for $10 billion, bringing to a close the pharmacy chain ...

As of fiscal 2024, the firm held roughly $3.1 billion in cash and equivalents with a total debt balance of $9 billion. The firm has done a great job in bringing this balance down over the last three ...

Walgreens (WBA) finalized an up to $27.3 billion deal to take itself private after four months of negotiations with Sycamore Partners, the companies announced Thursday. Sycamore is a New York-based ...

Vertex Pharmaceuticals’ (VRTX) non-opioid pain drug Journavx was picked up by UnitedHealth’s (UNH) Optum on “Tier 3.” The insurer said, ...

Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...

Vertex Pharma (VRTX) stock slips as UnitedHealth (UNH) offers its pain drug Journavx Tier 3 coverage, setting a rivalry with ...

Pharmacy benefit managers take considerably different approaches to managing patient access to biosimilars, or cheaper ...

The firm has done a great job in bringing this balance down over the last three years but we do see some potential risk in the near term. Roughly 40% of debt is set to expire over the next three years ...